ISPOR - PCN40 Cost-Utility Analysis of Pembrolizumab Versus Platinum Based Chemotherapy As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer (NSCLC) in UK

PCN40 Cost-Utility Analysis of Pembrolizumab Versus Platinum Based Chemotherapy As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer (NSCLC) in UK

Abstract

Authors

A. Maria D. Verma J. Verma

Full Text Cite This Article

Back to Volume 22, Supplemental S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now